Infliximab as First‐Line Therapy in Severe Pediatric Crohn Disease

Saved in:
Bibliographic Details
Published inJournal of pediatric gastroenterology and nutrition Vol. 43; no. 3; pp. 388 - 390
Main Authors Ridder, Lissy, Benninga, Marc A., Taminiau, Jan A. J. M., Hommes, Daniël W.
Format Journal Article
LanguageEnglish
Published Hagerstown, MD Lippincott Williams & Wilkins, Inc 01.09.2006
Lippincott
Subjects
Abdominal Pain
Antibodies, Monoclonal - therapeutic use
Azathioprine - therapeutic use
Biological and medical sciences
Blood Sedimentation
Child
Colon - pathology
Colonoscopy
Crohn Disease - diagnosis
Crohn Disease - drug therapy
Diarrhea
Duodenoscopy
Duodenum - pathology
Esophagus - pathology
Feeding. Feeding behavior
Female
Fundamental and applied biological sciences. Psychology
Gastroenterology. Liver. Pancreas. Abdomen
Gastroscopy
Humans
Ileum - pathology
Immunomodulators
Infliximab
Intestinal Mucosa - pathology
Medical sciences
Other diseases. Semiology
Pharmacology. Drug treatments
Remission Induction
Severity of Illness Index
Sigmoidoscopy
Stomach - pathology
Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
Vertebrates: anatomy and physiology, studies on body, several organs or systems
Weight Loss
Human
Pediatrics
Cytokine
Metabolic diseases
Monoclonal antibody
Inflammatory disease
Immunomodulator
Crohn disease
Treatment
Infliximab
Anticytokine
Gastroenterology
Digestive diseases
Intestinal disease
Immunosuppressive agent
Child
Tumor necrosis factor α
Online AccessGet full text

Cover

More Information
Bibliography:Conflict of interest: The first author received funding for research from the company that produces infliximab.
ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:0277-2116
1536-4801
DOI:10.1097/01.mpg.0000226369.31956.bf